Contact Us
Drug Search Results
More Filters [+]

Cariprazine

Alternative Names: cariprazine, rgh-188, mp-214, vraylar, cariprazinhydrochlorid, reagila
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Cariprazine is a medication that works in the brain to treat schizophrenia. It is also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Cariprazine rebalances dopamine and serotonin to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Cariprazine-(Vraylar))

Mechanisms of Action: 5-HT1A Partial Agonist,D2 Partial Agonist,D3 Partial Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: Bipolar Disorder | Depressive Disorder | Schizophrenia

Known Adverse Events: Depressive Disorder | Schizophrenia | Dyspepsia

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cariprazine

Countries in Clinic: Bulgaria, Korea, Malaysia, Poland, Puerto Rico, Romania, Russia, Serbia, Taiwan, Thailand, Ukraine, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Autism Spectrum Disorder|Bipolar Disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT04777357

P3

Recruiting

Bipolar Disorder

2027-03-10

NCT04578756

P3

Active, not recruiting

Bipolar Disorder|Autism Spectrum Disorder|Schizophrenia

2025-09-14

jRCT2031220096

P3

Recruiting

Schizophrenia

2025-04-25

M21-465

P3

Completed

Autism Spectrum Disorder

2024-10-04

Recent News Events

Date

Type

Title

10/29/2024

News Article

 AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario

10/24/2024

News Article

 AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions

09/04/2024

News Article

 AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

08/02/2024

News Article

 Anxiety Disorders Treatment Market Size to Reach USD 15.90 Bn by 2032

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions